Neurogene Inc
NGNE
Get informed when a big investor buys or sells
+ FollowMarket Cap$571.1M
Close$
$4.44
87.5% downside
Current Fair Value
87.5% downsideOvervalued by 87.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $571.10 Million |
|---|---|
| Enterprise Value | $466.96 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.24 |
| Beta | 1.95 |
| Outstanding Shares | 22,552,032 |
Return
| Return on Equity | -51.17% |
|---|---|
| Return on Assets | -45.47% |
| Return on Invested Capital | -53.82% |
Valuation & Multiples
| P/E Ratio | -6.56 |
|---|---|
| PEG | -11.58 |
| Price to Sales | - |
| Price to Book Ratio | 3.96 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.89 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.42
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2322▲ 23.22% |
|---|---|
| Total Calls | 165,400▲ 1554.00% |
| Total Puts | 38,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.08%▼ 1.90% |
|---|---|
| Total Invested | $341.97M▲ 0.48% |
| Investors Holding | 101▲ 7.00% |
ESG Score
No data
About Neurogene Inc
66 employeesneoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein d...